Get our latest issue now

available for iOS, Android and web

latest

Merck KGaA signs 134 million euro Parkinson's pact

World News | January 17, 2011


Kevin Grogan

Merck KGaA signs 134 million euro Parkinson's pact

Merck KGA has signed a deal to develop treatments for Parkinson's disease with French firm Domain Therapeutics.

Specifically, the company's Merck Serono unit has inked an exclusive development and licensing agreement with Domain to develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator drugs targeting Parkinson’s and other neurodegenerative diseases. The Strasbourg-headquartered company will contribute optimised compounds that have been developed from its proprietary chemical series, the partners noted.

Cashwise, Domain will receive 2 million euros in upfront payments and research funding, and is eligible for up to 132 million euros in milestones for the first two products, as well as undisclosed royalties.

mGluR4 is a glutamate receptor, a member of the G-protein coupled receptor (GPCR) family believed to be a potential therapeutic target for Parkinson’s. Bernhard Kirschbaum, head of R&D at Merck Serono, noted that Domain "has developed great expertise" in the GPCR area, adding that the partnership "reflects our long-term commitment to develop new treatments for neurodegenerative diseases".

Domain chief executive Pascal Neuville said the agreement is a validation of his company's business model, ie "addressing difficult GPCRs and partnering compounds, with a significant deal, at an early stage of development". He added that the Merck link-up "will enable us to sign further deals of this kind".

Click here to order a reprint of this news story.

Tags


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

JobSearch


Website Search


Search News Search Magazine